Sustained-release bupropion and bupropion/mecamylamine tablets
DCFirst Claim
Patent Images
1. A sustained release pharmaceutical tablet comprising:
- sustained release granules consisting essentially of bupropion hydrochloride admixed with a hydroxyalkylcellulose; and
an extragranular phase comprising a particulate material that provides a sustained release matrix;
said particulate material is selected from the group consisting of polyvinylacetate, blends of polyvinylacetate and polyvinylpyrrolidone, a vinylpyrrolidone copolymer and polyethylene oxide,the granules being distributed within the extragranular phase.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which then is coated, with a means to provide delayed release, such as with an enteric coating composition. The mecamylamine hydrochloride can be contained in a second granule comprising a hydroxyalkylcellulose.
167 Citations
10 Claims
-
1. A sustained release pharmaceutical tablet comprising:
-
sustained release granules consisting essentially of bupropion hydrochloride admixed with a hydroxyalkylcellulose; and an extragranular phase comprising a particulate material that provides a sustained release matrix;
said particulate material is selected from the group consisting of polyvinylacetate, blends of polyvinylacetate and polyvinylpyrrolidone, a vinylpyrrolidone copolymer and polyethylene oxide,the granules being distributed within the extragranular phase. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A sustained release pharmaceutical tablet comprising:
-
an uncoated sustained release granular phase comprising bupropion hydrochloride admixed with a hydroxyalkylcellulose; and an extragranular phase comprising a particulate material that provides a sustained release matrix;
said particulate material is selected from the group consisting of polyvinylacetate, blends of polyvinylacetate and polyvinylpyrrolidone, a vinylpyrrolidone copolymer and polyethylene oxide,the uncoated granular phase being distributed within the extragranular phase. - View Dependent Claims (7, 8, 9, 10)
-
Specification